GO:1905065 positive regulation of vascular associated smooth muscle cell differentiation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905065 describes any process that activates or increases the frequency, rate or extent of vascular smooth muscle cell (VSMC) differentiation, a biological process central to vessel wall homeostasis.
• VSMC differentiation is marked by expression of contractile proteins such as ACTA2, MYH11, CNN1 and TAGLN, and is controlled by transcription factors including myocardin, SRF and GATA6.
• Loss of the differentiated VSMC phenotype, termed phenotypic switching, contributes to atherosclerosis, arterial calcification and aortic aneurysm.
• Positive regulators of VSMC differentiation include GDF11, which prevents phenotype switching and aortic aneurysm formation, and SIRT6, which counteracts GATA6-driven senescence and calcification.
• Epigenetic and metabolic inputs, such as H19 upregulation and AMPK inhibition, can suppress the differentiated VSMC state and promote calcification.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of candidate regulators of GO:1905065 in vascular disease research.
Description
GO:1905065, positive regulation of vascular associated smooth muscle cell differentiation, is a Gene Ontology biological process term that captures any signal or molecular event that increases the frequency, rate or extent of vascular smooth muscle cell (VSMC) differentiation. VSMCs are the predominant cell type of the arterial media, and their differentiated state is defined by high-level expression of contractile proteins and a low rate of proliferation. The transition between differentiated and dedifferentiated states, often called phenotypic modulation or switching, is a hallmark of vascular remodeling and disease. Understanding what positively regulates VSMC differentiation is therefore central to vascular biology and to the development of therapies for atherosclerosis, arterial calcification and aneurysm. This article integrates the QuickGO definition with verified PubMed literature to summarize the mechanisms, key genes, disease links and experimental models relevant to GO:1905065.
positive regulation of vascular associated smooth muscle cell differentiation At A Glance
| GO ID | GO:1905065 |
|---|---|
| GO term | positive regulation of vascular associated smooth muscle cell differentiation |
| Ontology | biological_process |
| Synonym | activation of VSMC differentiation; positive regulation of VSMC differentiation; upregulation of vascular smooth muscle cell differentiation |
| Major function | Increases the frequency, rate or extent of VSMC differentiation, promoting a contractile, quiescent phenotype |
| Key regulators | GATA6, SIRT6, GDF11, H19, AMPK, TXNIP, VHL/HIF1a/KLF4 |
| Associated diseases | Arterial calcification, atherosclerosis, aortic aneurysm, aortic inflammation |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, ChIP-seq, lineage tracing, calcification assays |
What Is GO:1905065?
In our own words, GO:1905065 refers to any biological process that activates or increases the frequency, rate or extent of vascular smooth muscle cell differentiation. It is a positive regulatory node that sits upstream of the differentiated VSMC phenotype, encompassing transcription factor activity, epigenetic changes, signaling cascades and metabolic cues that together promote expression of contractile genes and suppress synthetic or macrophage-like programs.
Why Is positive regulation of vascular associated smooth muscle cell differentiation Important in Cell Biology?
GO:1905065 matters because the differentiated VSMC state is protective for the vessel wall, and its loss is a common denominator in major cardiovascular diseases. Positive regulators of VSMC differentiation, such as GDF11 and SIRT6, suppress phenotype switching, calcification and aneurysm formation, whereas their inactivation accelerates vascular pathology. Conversely, epigenetic and metabolic drivers such as H19 and AMPK inhibition can push VSMCs toward osteogenic or macrophage-like fates, linking GO:1905065 to atherosclerosis and inflammation. Thus, identifying and validating positive regulators of VSMC differentiation is a direct route to mechanistic biomarkers and therapeutic targets in vascular medicine.
• Maintains the contractile, quiescent VSMC phenotype that stabilizes the arterial wall.
• Suppresses phenotypic switching, a driver of atherosclerosis and plaque instability.
• Counteracts medial vascular calcification by limiting osteogenic transition of VSMCs.
• Prevents aortic aneurysm formation through regulators such as GDF11.
• Integrates epigenetic control, including H19 and AMPK-dependent pathways.
• Connects metabolic stress and S-adenosylhomocysteine hydrolase deficiency to calcification.
• Provides a mechanistic framework for SIRT6-GATA6 antagonism in VSMC senescence.
• Links thioredoxin-interacting protein (TXNIP) to smooth muscle cell fate in calcification.
• Offers CRISPR-tractable targets for causal validation in vascular disease models.
• Supports development of differentiation-preserving therapeutics for cardiovascular disease.
What Happens During positive regulation of vascular associated smooth muscle cell differentiation?
Initiation by transcriptional activators
In simple terms: Certain transcription factors switch on the genes that make a smooth muscle cell a smooth muscle cell.
Positive regulation of VSMC differentiation begins with transcription factors that activate contractile gene programs. Myocardin and SRF cooperate to drive expression of VSMC-restricted genes such as ACTA2 and MYH11, and the balance of these activators versus repressors determines the differentiated state. GATA6 can influence VSMC fate and senescence-related calcification, illustrating how transcription factor dosage shapes the differentiation outcome.
Epigenetic and metabolic modulation
In simple terms: Chemical marks on DNA and the cell's energy status can either lock in or loosen the differentiated state.
Epigenetic upregulation of H19 and concurrent AMPK inhibition contribute to atherosclerotic calcification by shifting VSMCs away from the contractile phenotype. SIRT6, an anti-aging deacetylase, counteracts GATA6-driven senescence and DNA damage repair defects in VSMCs, thereby supporting the differentiated state. These findings show that positive regulation of VSMC differentiation is sensitive to chromatin and metabolic inputs.
Signaling inputs that reinforce differentiation
In simple terms: External signals tell the smooth muscle cell to stay differentiated rather than switch to a synthetic or inflammatory fate.
GDF11 regulates VSMC phenotype switching to prevent aortic aneurysm formation, acting as a positive regulator of the differentiated state. Estrogen signaling can also influence VSMC fate, as high estrogen induces trans-differentiation of VSMCs to a macrophage-like phenotype via inhibition of the VHL/HIF1a/KLF4 axis, indicating that hormonal signals can either support or oppose differentiation depending on context. TXNIP deletion in smooth muscle cells ameliorates medial vascular calcification, linking redox signaling to the maintenance of VSMC identity.
Contractile gene expression and phenotype stabilization
In simple terms: Once the differentiation program is on, the cell builds contractile proteins and stops behaving like a proliferating synthetic cell.
The endpoint of positive regulation of VSMC differentiation is robust expression of contractile markers and suppression of synthetic markers. Expressional regulation of smooth muscle cell-specific genes is tightly coupled to phenotypic modulation, and sustained activator signaling is required to maintain the contractile state. Matricellular proteins in the vessel wall can further modulate this balance during atherosclerosis development. Disruption of positive regulators, such as loss of SIRT6 or GDF11 signaling, tips the balance toward dedifferentiation and disease.
Key Genes Involved in GO:1905065 positive regulation of vascular associated smooth muscle cell differentiation
The following genes and proteins have been experimentally linked to positive regulation of vascular associated smooth muscle cell differentiation or to its dysregulation in vascular disease.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GATA6 | Transcription factor that accelerates VSMC senescence-related calcification and counteracts SIRT6 | Target for studying senescence and calcification in VSMCs |
| SIRT6 | Anti-aging deacetylase that supports DNA damage repair and opposes GATA6 | Positive regulator of VSMC differentiation and genomic stability |
| GDF11 | Regulates VSMC phenotype switching to prevent aortic aneurysm | Candidate therapeutic for aneurysm and phenotype maintenance |
| TXNIP | Smooth muscle cell-specific deletion ameliorates medial vascular calcification | Links redox signaling to VSMC fate in calcification |
| H19 | Epigenetically upregulated lncRNA contributing to atherosclerotic calcification | Epigenetic regulator of VSMC phenotype |
| AMPK | Inhibition concurrently contributes to calcification with H19 upregulation | Metabolic node controlling VSMC differentiation |
| VHL | Part of VHL/HIF1a/KLF4 axis inhibited by high estrogen in VSMC trans-differentiation | Hypoxia-related regulator of VSMC fate |
| HIF1a | Effector in VHL/HIF1a/KLF4 axis during macrophage-like trans-differentiation | Oxygen-sensing regulator of VSMC phenotype |
| KLF4 | Transcription factor in VHL/HIF1a/KLF4 axis linked to VSMC trans-differentiation | Known regulator of VSMC phenotypic switching |
| ACTA2 | Smooth muscle alpha-actin, a canonical contractile marker | Readout of differentiated VSMC state |
| MYH11 | Smooth muscle myosin heavy chain, contractile marker | Marker of mature VSMC differentiation |
| CNN1 | Calponin 1, contractile protein of VSMCs | Differentiation marker in expression studies |
| TAGLN | SM22-alpha, actin-binding contractile protein | Common VSMC differentiation marker |
| SRF | Serum response factor cooperating with myocardin to activate contractile genes | Core transcriptional activator of VSMC differentiation |
| Myocardin | Coactivator of SRF driving VSMC-specific gene expression | Master positive regulator of VSMC differentiation |
| Matricellular proteins | Extracellular matrix proteins modulating VSMC behavior in atherosclerosis | Microenvironmental regulators of phenotype |
How Is positive regulation of vascular associated smooth muscle cell differentiation Regulated?
Positive regulation of VSMC differentiation is controlled by an integrated network of transcription factors, epigenetic modifiers and metabolic sensors. GATA6 and SIRT6 act antagonistically, with GATA6 accelerating senescence-related calcification while SIRT6 preserves DNA repair and the differentiated state. GDF11 signaling reinforces the contractile phenotype and prevents aneurysm formation. Epigenetic upregulation of H19 together with AMPK inhibition promotes calcification and loss of differentiation, showing that metabolic stress can override positive regulatory inputs. Hormonal signals such as estrogen can redirect VSMCs toward a macrophage-like phenotype via the VHL/HIF1a/KLF4 axis, indicating context-dependent regulation. Redox balance, exemplified by TXNIP, also modulates medial calcification and VSMC fate.
positive regulation of vascular associated smooth muscle cell differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GATA6 | VSMC senescence-related arterial calcification | VSMC-specific knockout or overexpression in calcification models |
| SIRT6 | DNA damage repair and anti-aging in VSMCs | Knockout and rescue in VSMC senescence assays |
| TXNIP | Medial vascular calcification | Smooth muscle cell-specific deletion in mouse calcification models |
| GDF11 | Aortic aneurysm and phenotype switching | Knockout or supplementation in aneurysm models |
| H19 / AMPK | Atherosclerotic calcification | Epigenetic perturbation and metabolic assays in VSMCs |
Arterial calcification and VSMC senescence
Loss of positive regulation of VSMC differentiation contributes to medial and atherosclerotic calcification. GATA6 accelerates VSMC senescence-related arterial calcification by counteracting SIRT6 and impeding DNA damage repair, whereas SIRT6 supports the differentiated state. Smooth muscle cell-specific deletion of TXNIP ameliorates medial vascular calcification, linking redox control to VSMC fate. Epigenetic H19 upregulation and AMPK inhibition concurrently promote atherosclerotic calcification, further demonstrating that suppressing differentiation drives mineral deposition.
Atherosclerosis and phenotypic switching
Phenotypic switching of VSMCs from a contractile to a synthetic state is a hallmark of atherosclerosis. Matricellular proteins in the vessel wall modulate VSMC behavior and plaque development. Expressional regulation of smooth muscle cell-specific genes is tightly associated with phenotypic modulation, and loss of positive regulators tips the balance toward disease. High estrogen can induce trans-differentiation of VSMCs to a macrophage-like phenotype, resulting in aortic inflammation via inhibition of the VHL/HIF1a/KLF4 axis.
Aortic aneurysm
GDF11 regulates VSMC phenotype switching to prevent aortic aneurysm formation, identifying positive regulation of VSMC differentiation as a protective mechanism in aneurysm pathogenesis. This aligns with the broader concept that maintaining the contractile VSMC state preserves vessel wall integrity.
From positive regulation of vascular associated smooth muscle cell differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for VSMC differentiation? | CRISPR knockout in primary VSMCs or smooth muscle cell lines |
| Does a specific point mutation alter transcriptional activity? | CRISPR point-mutation knock-in at the endogenous locus |
| Does a risk variant affect differentiation? | Knock-in of the variant allele followed by contractile marker profiling |
| Where and when is the protein expressed? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression rescue differentiation? | Lentiviral or CRISPR activation overexpression in dedifferentiated VSMCs |
| Does loss of function worsen calcification? | Smooth muscle cell-specific conditional knockout in mouse models |
How to Study the positive regulation of vascular associated smooth muscle cell differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome and contractile gene expression | Identifying positive regulators of VSMC differentiation |
| ChIP-seq | Transcription factor binding at target loci | Mapping GATA6, SIRT6 and SRF occupancy |
| ATAC-seq | Chromatin accessibility | Assessing epigenetic changes during phenotype switching |
| Alizarin red / calcium assay | Mineralization of VSMC cultures | Testing calcification phenotypes after gene perturbation |
| Immunofluorescence | Contractile protein expression and localization | Confirming differentiated VSMC state |
| Western blot | Protein levels of contractile and signaling proteins | Validating GDF11 or SIRT6 pathway activity |
| Lineage tracing | Origin and fate of VSMCs in vivo | Tracking trans-differentiation in aortic inflammation |
| CRISPR screening | Phenotypic hits across a gene library | Discovering novel positive regulators of VSMC differentiation |
Transcriptomic profiling of VSMC differentiation
RNA-seq of VSMCs under differentiation-promoting or -suppressing conditions reveals contractile gene signatures and pathways linked to GO:1905065. Expressional regulation of smooth muscle cell-specific genes is a classic readout of phenotypic modulation. Comparative transcriptomics can identify positive regulators such as GDF11-responsive genes.
Epigenetic and chromatin assays
ChIP-seq and ATAC-seq can map transcription factor occupancy and chromatin accessibility at contractile gene loci. GATA6 and SIRT6 antagonism involves chromatin-level regulation of senescence and DNA repair genes. Epigenetic upregulation of H19 illustrates how non-coding RNA and DNA methylation changes contribute to calcification.
Functional calcification and phenotype assays
Alizarin red staining, calcium quantification and contractile marker immunostaining are standard assays to test whether a gene positively regulates VSMC differentiation. TXNIP deletion ameliorates medial calcification, and GATA6 promotes calcification, providing validated phenotypic endpoints. Macrophage-like trans-differentiation can be assessed by marker expression after estrogen or VHL/HIF1a/KLF4 perturbation.
In vivo vascular models
Mouse models of aortic aneurysm and vascular calcification allow causal testing of positive regulators. GDF11 regulation of phenotype switching prevents aneurysm formation in vivo. Smooth muscle cell-specific deletions, such as TXNIP, demonstrate cell-autonomous effects on medial calcification.
How CRISPR Can Be Used to Study GO:1905065 positive regulation of vascular associated smooth muscle cell differentiation
Knockout
CRISPR knockout of candidate genes in VSMCs or mouse models tests whether a factor is required for positive regulation of VSMC differentiation. Smooth muscle cell-specific deletion of TXNIP ameliorates medial vascular calcification, demonstrating the power of knockout approaches. Knockout of SIRT6 or GATA6 can reveal their antagonistic roles in senescence and calcification.
Point Mutation
Point-mutation knock-in allows precise testing of phosphorylation sites, DNA-binding residues or disease-associated variants in regulators of VSMC differentiation. Such edits can dissect whether a specific residue in GATA6 or SIRT6 is required for their opposing functions. Variants identified in epigenetic regulators like H19 can be modeled to assess effects on calcification.
Knock-in
Knock-in of reporters, tags or human disease alleles enables tracking of VSMC differentiation in vivo. Tagged knock-in of contractile proteins such as ACTA2 or MYH11 allows live imaging of the differentiated state. Knock-in of risk alleles in GDF11 or its pathway can test causality in aneurysm models.
Overexpression
CRISPR activation or lentiviral overexpression of positive regulators can rescue or enhance VSMC differentiation. Overexpression of GDF11 or SIRT6 may reinforce the contractile phenotype and protect against calcification or aneurysm. Conversely, overexpression of GATA6 or H19 can drive dedifferentiation and calcification, providing gain-of-function evidence.
How EDITGENE Supports positive regulation of vascular associated smooth muscle cell differentiation Research
Researchers studying positive regulation of vascular associated smooth muscle cell differentiation-related genes often need to determine whether a candidate gene is causally involved in maintaining or disrupting the contractile VSMC state. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell and animal models, enabling rigorous testing of hypotheses derived from transcriptomic, epigenetic and genetic studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of vascular associated smooth muscle cell differentiation research.
Frequently Asked Questions About positive regulation of vascular associated smooth muscle cell differentiation
What is GO:1905065?
GO:1905065 is the Gene Ontology term for positive regulation of vascular associated smooth muscle cell differentiation, describing any process that increases the frequency, rate or extent of VSMC differentiation.
What genes are involved in positive regulation of vascular associated smooth muscle cell differentiation?
Key genes include GATA6, SIRT6, GDF11, TXNIP, H19, AMPK, VHL, HIF1a and KLF4, as well as contractile markers ACTA2, MYH11, CNN1 and TAGLN.
Why is VSMC differentiation important in vascular disease?
Maintaining the differentiated VSMC state protects against atherosclerosis, arterial calcification and aortic aneurysm, whereas phenotypic switching promotes disease.
How does GATA6 regulate VSMC differentiation?
GATA6 accelerates VSMC senescence-related arterial calcification by counteracting SIRT6 and impeding DNA damage repair, thereby opposing the differentiated state.
What role does GDF11 play in VSMC phenotype switching?
GDF11 regulates VSMC phenotype switching to prevent aortic aneurysm formation, acting as a positive regulator of the contractile phenotype.
How is H19 linked to VSMC calcification?
Epigenetic upregulation of H19 together with AMPK inhibition concurrently contributes to atherosclerotic calcification, promoting loss of VSMC differentiation.
Can CRISPR be used to study VSMC differentiation?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of genes regulating VSMC differentiation in vitro and in vivo.
What experimental models are used for GO:1905065 research?
Common models include primary VSMC cultures, smooth muscle cell-specific knockout mice, calcification assays and aneurysm models.
What is the role of TXNIP in vascular calcification?
Smooth muscle cell-specific deletion of TXNIP ameliorates medial vascular calcification, indicating that TXNIP promotes calcification and opposes the differentiated state.
How does estrogen affect VSMC phenotype?
High estrogen can induce trans-differentiation of VSMCs to a macrophage-like phenotype via inhibiting the VHL/HIF1a/KLF4 axis, resulting in aortic inflammation.
Conclusion
GO:1905065, positive regulation of vascular associated smooth muscle cell differentiation, is a central node in vascular biology that integrates transcriptional, epigenetic and metabolic inputs to maintain the contractile VSMC phenotype. Its dysregulation underlies calcification, atherosclerosis and aneurysm, making its regulators attractive therapeutic targets. CRISPR-based models provide the causal evidence needed to translate these findings into new strategies for cardiovascular disease.
References
- 1. Li X et al.. 2024. The transcription factor GATA6 accelerates vascular smooth muscle cell senescence-related arterial calcification by counteracting the role of anti-aging factor SIRT6 and impeding DNA damage repair.. Kidney Int 105(1):115-131 PMID: 37914087
- 3. Hwang AR et al.. 2025. Smooth muscle cell-specific deletion of TXNIP ameliorates medial vascular calcification.. Exp Mol Med 57(7):1519-1535 PMID: 40610750
- 4. Pervaiz N et al.. 2023. Matricellular proteins in atherosclerosis development.. Matrix Biol 120:1-23 PMID: 37086928
- 5. Sobue K et al.. 1999. Expressional regulation of smooth muscle cell-specific genes in association with phenotypic modulation.. Mol Cell Biochem 190(1-2):105-18 PMID: 10098977
- 6. Su X et al.. 2026. GDF11 Regulates Vascular Smooth Muscle Cell Phenotype Switching to Prevent Aortic Aneurysm Formation.. Cardiovasc Drugs Ther 40(3):883-895 PMID: 41240221
- 7. Dai X et al.. 2022. Epigenetic Upregulation of H19 and AMPK Inhibition Concurrently Contribute to S-Adenosylhomocysteine Hydrolase Deficiency-Promoted Atherosclerotic Calcification.. Circ Res 130(10):1565-1582 PMID: 35410483
- 8. Zhang R et al.. 2024. High estrogen induces trans-differentiation of vascular smooth muscle cells to a macrophage-like phenotype resulting in aortic inflammation via inhibiting VHL/HIF1a/KLF4 axis.. Aging (Albany NY) 16(11):9876-9898 PMID: 38843385
